Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|62|1|129-134

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.62, Iss.1, 2015-07, pp. : 129-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1793-1797

John Wiley & Sons Inc

Access to resources Recommend Favorite

Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E146-E154

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct‐acting antivirals

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E372-E378

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1013-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1013-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite